Pseudo-pharma VC Index signs five year manufacturing deal with Lonza
This article was originally published in Scrip
In what may represent another nail in the coffin of the stand-alone biotech company model, pharma-backed venture capitalist Index Ventures has taken an "unusual" step of signing an exclusive agreement with a major contract manufacturing organization to develop and manufacture the biologics of all its portfolio companies. The move, which could be first of many, underlines Index’ asset-based investment approach in which the investor acts, in development at least, as a pseudo-pharmaceutical company.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.